Multiple Sclerosis Lupus Rheumatoid Arthritis Coeliac Disease Myasthenia Gravis Type 1 Diabetes Celiac Disease Graves' Disease Psoriasis Cancer
The program narrows to non‑relapsing secondary progressive MS, with the U.S. decision now expected by the end of the first quarter of 2026.